Key Highlights
- Faron Pharmaceuticals (LSE:FARN) rose by 3.13% on 27 October, 2026.
- The latest announcement, dated 19 October, 2026, confirmed final melanoma survival data from the MATINS study at ESMO 2026.
- Cash and cash equivalents stood at EUR 32.0 million at 30 June, 2026, following a EUR 40.1 million rights issue.
- A randomised Phase 2b trial, BEXERA, is planned in frontline higher-risk myelodysplastic syndrome.
- The company is pre-revenue and does not pay a dividend.
Faron Pharmaceuticals Ltd is a Turku-based clinical-stage biopharmaceutical company developing immunotherapies for cancer, with shares quoted on AIM under the ticker LSE:FARN.
Why Did Faron Pharmaceuticals (LSE:FARN) Rise by 3.13% on 27 October, 2026?
Faron Pharmaceuticals (LSE:FARN) advanced by 3.13% on 27 October, 2026. A review of the company's official newsroom shows no announcement dated 27 October, 2026, so no single disclosure can be named as the reason for the move.
The most recent verified developments provide context. On 19 October, 2026, Faron said it would report final overall survival data from the melanoma cohort of the Phase 1/2 MATINS study at the ESMO Congress 2026 in Madrid, which runs from 23 to 27 October, 2026.
On 1 October, 2026, the first patient was dosed in the BLAZE investigator-initiated trial, which combines bexmarilimab with nivolumab in patients with acquired resistance to anti-PD-1 therapy. The company also held an R&D Day on 8 October, 2026, covering the bexmarilimab programme in haematological and solid tumour settings.
The business model of Faron Pharmaceuticals (LSE:FARN)
Faron is built around bexmarilimab, a wholly owned, first-in-class humanised antibody that binds Clever-1, a receptor on immunosuppressive macrophages. The aim is to reprogramme the tumour microenvironment so that the immune system can respond more effectively to cancer.
The company generates no product revenue. Its model relies on advancing bexmarilimab through clinical development, securing regulatory feedback and funding progress through equity raises and debt-like instruments.
The lead programme is BEXMAB, a Phase 1/2 study of bexmarilimab with azacitidine in acute myeloid leukaemia and myelodysplastic syndrome (MDS). The EMA and FDA have granted orphan drug designation in MDS.
Major Reasons Behind Upside
- Late-stage MDS planning: The half-year report describes BEXERA as a randomised Phase 2b trial in frontline, treatment-naive higher-risk MDS, planned to start in the second half of 2026, with 90 participants.
- Regulatory clarity: An End-of-Phase 2 meeting with the FDA, announced on 18 August, 2025, confirmed the study design and an accelerated approval pathway for frontline patients.
- Clinical data: At EHA 2026, median duration of complete remission in treatment-naive higher-risk MDS was reported at 16.1 months with bexmarilimab plus azacitidine.
- Balance sheet repair: Equity moved from EUR (16.7) million a year earlier to EUR 11.6 million at 30 June, 2026, after the rights issue.
What Are the Major Risks Investors Should Consider?
- Execution risk: BEXERA must start on schedule and enrol 90 participants across many sites, and trial delays would extend the cash requirement.
- Funding risk: The half-year loss was EUR 8.5 million, and borrowings totalled about EUR 17.8 million at 30 June, 2026. On 30 September, 2026, a convertible bond amortisation payment was deferred by mutual agreement with the lender.
- Regulatory risk: An accelerated approval pathway is not a guarantee, and the FDA and EMA may require additional data.
- Operational challenges: The company relies on contract research partners, investigator-led trials and external manufacturing to deliver its programme.
- Market risk: Small-cap biotechnology shares can move sharply on trial news, conference data and financing announcements.
- Competitive pressure: The MDS treatment landscape is evolving, and larger groups are pursuing competing approaches.
What Is the Dividend Outlook?
Faron is a clinical-stage company with no product revenue and an accumulated deficit of EUR 222.9 million at 31 December, 2025. The Board proposed no dividend for the 2025 financial year, and capital is directed to clinical development.
How Does Faron Pharmaceuticals (LSE:FARN) Compare With Other Industry Peers?
Faron sits among small and mid-sized clinical-stage immuno-oncology companies listed in London, the Nordics and the United States. Most share its profile of no revenue and dependence on external capital.
Its differentiators are a single wholly owned lead asset with a novel target, orphan designations in MDS, and an FDA-confirmed pathway for frontline patients. Its constraints are a modest cash position by sector standards, a convertible bond structure and a concentrated pipeline. Larger oncology companies hold diversified portfolios and commercial income, so comparison is most useful through trial milestones, cash runway and regulatory progress.
What Are the Bull and Bear Cases for LSE:FARN?
Bull Case:
- BEXERA starts on schedule and enrols efficiently, advancing the accelerated approval pathway.
- Further overall survival and remission data in MDS reinforce the clinical profile of bexmarilimab.
- The completed rights issue gives management room to reach the next major milestones.
- Orphan designations support the regulatory framework in MDS.
- Solid tumour trials broaden the programme at limited cost.
Bear Case:
- Trial delays or weaker randomised data could challenge the development thesis.
- The convertible bond structure and the September payment deferral keep financing in focus.
- Further capital raising may dilute existing shareholders.
- Melanoma data show a disease control rate of 20% and median overall survival of 7.6 months, a modest profile in a refractory population.
- A single-asset pipeline concentrates risk.
Technical Levels to Watch
- Support Zone: Investors often look at prior consolidation areas where buying interest has previously emerged after pullbacks.
- Resistance Levels: Earlier swing highs and congestion areas may cap rallies until volume confirms a breakout.
- Volume Trends: Rising turnover on advances suggests broader participation, while thin volume can exaggerate moves in small-cap shares.
- Momentum Indicators: Oscillators such as the relative strength index and moving average convergence divergence help gauge whether recent gains are sustained or stretched.
What Does the ESG Investment Case Look Like?
For a clinical-stage oncology company, the social dimension is central. Faron develops therapies for cancers with high unmet need, including higher-risk MDS and refractory melanoma, and works with academic centres and patient-focused organisations such as Blood Cancer United through its Therapy Acceleration Program.
Governance considerations include the use of convertible instruments, option plans and warrant issuance, which can affect shareholder dilution. Environmental impact is limited given the company's asset-light, outsourced operating model. Investors may wish to monitor future disclosure on trial ethics and board oversight.
Outlook
Faron enters the final quarter of 2026 with funding from its completed rights issue and a clear sequence of catalysts: the start of BEXERA, further data from MDS and solid tumour studies and continued conference presentations. The company does not provide a short-term financial outlook. Today's 3.13% rise has no identified company-specific trigger, and future moves will depend on delivery against the milestones above.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...